我武生物(300357) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 197,587,530.67, representing a 20.00% increase compared to CNY 164,654,385.39 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2022 was CNY 91,735,430.39, a 30.21% increase from CNY 70,454,208.66 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 76,730,047.57, up 27.68% from CNY 60,097,081.22 in the previous year[3]. - Basic earnings per share for Q1 2022 were CNY 0.1752, reflecting a 30.16% increase from CNY 0.1346 in the previous year[3]. - The net profit for the current period is 88,969,235.15, compared to 67,726,952.32 in the previous period, representing an increase of approximately 31.2%[28]. - The total profit for the current period is 106,121,775.74, up from 80,882,386.26 in the previous period, indicating a growth of about 31.2%[28]. - The operating profit for the current period is 104,953,424.10, compared to 80,960,799.18 in the previous period, reflecting an increase of approximately 29.6%[28]. - The total comprehensive income attributable to the parent company's owners is 91,733,178.17, compared to 70,455,445.49 in the previous period, representing an increase of about 30.2%[30]. Cash Flow and Assets - The net cash flow from operating activities decreased by 44.38% to CNY 55,592,478.71, down from CNY 99,954,766.48 in the same period last year[3]. - The cash flow from operating activities for the current period is 55,592,478.71, down from 99,954,766.48 in the previous period, a decrease of approximately 44.2%[35]. - The cash and cash equivalents at the end of the period amount to 298,128,769.36, down from 376,413,028.97 in the previous period, a decrease of approximately 20.7%[38]. - The net cash flow from investing activities is -36,137,641.70, compared to 56,741,590.98 in the previous period, indicating a decline in cash flow from investments[35]. - The total operating cash inflow for the current period is 229,210,561.85, compared to 208,110,123.73 in the previous period, an increase of about 10.1%[32]. - The total operating cash outflow for the current period is 173,618,083.14, compared to 108,155,357.25 in the previous period, an increase of approximately 60.5%[35]. - As of March 31, 2022, the cash and cash equivalents amount to 722,401,521.65 RMB, an increase from 649,994,339.83 RMB at the beginning of the year[15]. - The company's total assets at the end of the reporting period were CNY 1,972,265,388.56, a 2.09% increase from CNY 1,931,961,023.89 at the end of the previous year[3]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,044[9]. - Zhejiang Wawu Management Consulting Co., Ltd. holds 38.86% of shares, totaling 203,454,131 shares[9]. - Hu Gengxi holds 10.34% of shares, totaling 54,150,370 shares, with 40,612,777 shares pledged[9]. - The company has a total of 52,552,708 restricted shares, with 40,612,777 shares released from restrictions for Hu Gengxi[13]. - The company has not disclosed any related party relationships among the top ten shareholders[12]. - The company has a total of 4.01% of shares held by the National Social Security Fund, totaling 20,992,738 shares[9]. Research and Development - R&D expenses increased by 33.25% to CNY 6,699,422.29, reflecting the company's increased investment in research and development[6]. - Research and development expenses for the current period were ¥26,850,068.69, compared to ¥20,150,646.40 in the previous period, reflecting a rise of approximately 33.16%[25]. - The company completed Phase III clinical trials for "Artemisia Annua Pollen Allergen Sublingual Drops" for children with rhinitis[14]. - The company has received acceptance notifications for multiple drug applications, including "Liu Cao Pollen Puncture Liquid" and "Artemisia Annua Pollen Allergen Sublingual Drops" in January 2022[14]. Operating Costs - Total operating costs amounted to ¥108,106,533.70, up from ¥95,287,072.98, indicating an increase of about 13.91%[25]. - The company's total liabilities decreased to ¥86,693,850.02 from ¥135,356,468.28, a reduction of approximately 35.94%[21]. - The total equity attributable to shareholders of the parent company increased to ¥1,827,801,113.50 from ¥1,736,067,935.33, marking a growth of about 5.27%[24]. - The company's stock issuance approval from the China Securities Regulatory Commission has automatically expired[14]. - The company’s contract liabilities increased to ¥658,795.28 from ¥417,459.94, reflecting a growth of approximately 57.73%[21].